000890312 000__ 05382cam\a2200541Ki\4500
000890312 001__ 890312
000890312 005__ 20230306150055.0
000890312 006__ m\\\\\o\\d\\\\\\\\
000890312 007__ cr\un\nnnunnun
000890312 008__ 190518s2019\\\\sz\\\\\\o\\\\\000\0\eng\d
000890312 019__ $$a1096764384$$a1103806237
000890312 020__ $$a9783030113926$$q(electronic book)
000890312 020__ $$a3030113922$$q(electronic book)
000890312 020__ $$z9783030113919
000890312 020__ $$a149398876X
000890312 020__ $$a9781493988761
000890312 0247_ $$a10.1007/978-3-030-11392-6$$2doi
000890312 035__ $$aSP(OCoLC)on1101028668
000890312 035__ $$aSP(OCoLC)1101028668$$z(OCoLC)1096764384$$z(OCoLC)1103806237
000890312 040__ $$aEBLCP$$beng$$erda$$cEBLCP$$dGW5XE$$dYDXIT$$dOCLCO$$dEBLCP$$dAU@$$dYDX$$dUPM$$dUKMGB$$dOCLCF
000890312 049__ $$aISEA
000890312 050_4 $$aRC643$$b.C47 2019
000890312 08204 $$a616.99/419$$223
000890312 24500 $$aChronic Lymphocytic Leukemia  /$$cMichael Hallek, Barbara Eichhorst, Daniel Catovsky, editors.
000890312 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2019]
000890312 300__ $$a1 online resource (171 pages).
000890312 336__ $$atext$$btxt$$2rdacontent
000890312 337__ $$acomputer$$bc$$2rdamedia
000890312 338__ $$aonline resource$$bcr$$2rdacarrier
000890312 347__ $$atext file$$bPDF$$2rda
000890312 4901_ $$aHematologic Malignancies
000890312 5050_ $$aIntro; Contents; Part I: Pathophysiology; 1: Chronic Lymphocytic Leukemia: Who, How, and Where?; 1.1 Introduction; 1.2 Who; 1.2.1 Genetic Predisposition to CLL; 1.2.2 Monoclonal B-Cell Lymphocytosis; 1.2.3 Cell of Origin; 1.3 How; 1.3.1 Mechanisms of Leukemogenesis; 1.3.2 Genetic Defects; 1.3.3 B-Cell Receptor; 1.4 Where; 1.4.1 Microenvironmental Stimuli; 1.4.2 Cellular Components; 1.5 Conclusions; References; Part II: Diagnostics; 2: Laboratory Diagnosis of Chronic Lymphocytic Leukaemia; 2.1 Introduction; 2.2 Full/Complete Blood Count; 2.3 Morphology; 2.4 Immunophenotype
000890312 5058_ $$a2.5 CLL Diagnostic Algorithms Based on Immunophenotype 2.5.1 CLL Scoring Systems; 2.5.2 ERIC/ESCCA Approach to Improving Diagnostic Reproducibility; 2.6 Molecular Diagnostics; 2.6.1 Chromosomal Deletions and Aneuploidy; 2.6.2 Chromosomal Translocations; 2.6.3 The Immunoglobulin Gene; 2.6.4 Other Molecular Abnormalities; 2.7 Differential Diagnosis; 2.7.1 Mantle Cell Lymphoma; 2.7.2 B-Prolymphocytic Leukaemia; 2.7.3 Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma; 2.7.4 Cold Agglutinin Disease (CAD); 2.7.5 Monoclonal B-Cell Lymphocytosis
000890312 5058_ $$a2.8 Richter's Syndrome/Large Cell Transformation 2.9 Summary; References; Part III: Clinical Presentation; 3: The Clinical Presentation of CLL; 3.1 Introduction; 3.2 Demographics; 3.2.1 Incidence; 3.2.2 Age Distribution; 3.2.3 Gender; 3.3 Clinical Features; 3.3.1 Presentation; 3.3.2 Lymphoid Involvement; 3.3.3 Extramedullary Features; 3.3.4 Constitutional Symptoms; 3.3.5 Second Malignancies; 3.4 Laboratory Investigations; 3.4.1 Full Blood Count; 3.4.2 Other Blood Tests; 3.4.3 Bone Marrow (BM) Examination; 3.4.4 Imaging Tests; 3.4.5 Cytogenetics/Molecular Investigations
000890312 5058_ $$a4.3.9.1 Recurrent Acquired Single Nucleotide Variants (SNV) in CLLNOTCH1; SF3B1; 4.3.9.2 Hierarchical Model Integrating Prognostic Information from Genomic Studies; 4.3.9.3 Predicting the Risk of High-Grade Transformation; 4.4 Prognostic Markers in the Era of Novel Therapies; 4.5 Outlook; References; Part V: Treatment; 5: Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update; 5.1 Introduction; 5.2 Clinical Relevance of Genetic or Genomic Alterations Found in CLL, Including Mutations of the TP53 Gene
000890312 506__ $$aAccess limited to authorized users.
000890312 520__ $$aThis book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapy of T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed. 
000890312 588__ $$aDescription based on online resource; title from digital title page (viewed on May 22, 2019).
000890312 650_0 $$aChronic lymphocytic leukemia.
000890312 7001_ $$aHallek, Michael,$$eeditor.
000890312 7001_ $$aEichhorst, Barbara,$$eeditor.
000890312 7001_ $$aCatovsky, Daniel,$$eeditor.
000890312 77608 $$iPrint version:$$aHallek, Michael$$tChronic Lymphocytic Leukemia$$dCham : Springer,c2019$$z9783030113919
000890312 830_0 $$aHematologic malignancies (Series)
000890312 852__ $$bebk
000890312 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-11392-6$$zOnline Access$$91397441.1
000890312 909CO $$ooai:library.usi.edu:890312$$pGLOBAL_SET
000890312 980__ $$aEBOOK
000890312 980__ $$aBIB
000890312 982__ $$aEbook
000890312 983__ $$aOnline
000890312 994__ $$a92$$bISE